Related Experiment Video
Updated: Jun 19, 2026

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma
Published on: March 11, 2014
RNA interference silences the human papillomavirus 6b/11 early gene E7 in vitro and in vivo
1Department of Dermatology, School of Medicine, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou City, China.
Background:
RNA interference (RNAi) is a potential therapeutic tool in the treatment of various diseases, such as cancers and viral infections. Silencing of E7 genes is an effective method to suppress human papilloma virus (HPV)-related tumours.
Aim:
To determine the therapeutic potential of RNAi in controlling condyloma acuminatum (CA).
Methods:
Small interfering (si)RNA duplexes or small-hairpin (sh)RNA-expressing plasmids targeting the E7 genes of HPV-6b or HPV-11were inoculated into cultured E7-expressing cells via cationic liposomes, or into E7 gene-expressing mouse tumour models intratumorally or intravenously. Experiments were performed in triplicate and E7 mRNA level was analysed by real-time PCR.
Results:
The in vitro experiments found that both siRNAs and shRNA-expressing plasmids reduced the mRNA levels of HPV-6b or HPV-11 E7 to 20-40% at the optimum dosage of 25-50 nmol/L for siRNAs and 0.1-0.2 microg/mL for shRNA-expressing vectors. The optimum time for this to happen was 72 h. E7 mRNA expression in tumour models was reduced to 45-50% after three intratumural injections. Intratumoral injections of RNAi effectors induced greater inhibition than did intravenous injections.
Conclusions:
We conclude that HPV-6b/11 E7 gene expression can be specifically modulated by RNAi, which may provide a useful method in the management of CA.
Insights
RNA interference (RNAi) effectively suppressed human papillomavirus (HPV) E7 gene expression in cell cultures and mouse models. This demonstrates RNAi
Area of Science:
- Molecular Biology
- Gene Therapy
- Virology
Background:
- RNA interference (RNAi) shows therapeutic promise for diseases like cancer and viral infections.
- Targeting human papillomavirus (HPV) E7 genes is a viable strategy for HPV-related tumors.
Purpose of the Study:
- To evaluate the therapeutic efficacy of RNAi in managing condyloma acuminatum (CA).
Main Methods:
- Small interfering (si)RNA duplexes and small-hairpin (sh)RNA-expressing plasmids targeting HPV-6b/11 E7 genes were used.
- Inoculation was performed in cultured cells and HPV E7 gene-expressing mouse tumor models via cationic liposomes, intratumorally, or intravenously.
- Efficacy was assessed by measuring E7 mRNA levels using real-time PCR.
Main Results:
- In vitro, siRNAs and shRNA-expressing plasmids reduced HPV-6b/11 E7 mRNA levels to 20-40% at optimal concentrations and 72 hours.
- In vivo, three intratumoral injections reduced E7 mRNA expression by 45-50%.
- Intratumoral delivery demonstrated superior inhibition compared to intravenous administration.
Conclusions:
- RNAi can specifically modulate HPV-6b/11 E7 gene expression.
- RNAi presents a potential therapeutic approach for managing condyloma acuminatum.
Related Concept Videos
In vitro Mutagenesis
Experimental RNAi
In-vitro Mutagenesis
Mechanisms of Retrovirus-induced Cancers
Mechanisms of Retrovirus-induced Cancers
Initiation of Translation
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...

